Ask Question
Sign Guest book

 
About Lymphoma
| Advocacy & Art | CAM & Life Style | Clinical trials | Doctors & Centers  | Guidelines  at  Diagnosis | How  to   Help  | Research | Side Effects  | Support | Symptoms  | Tests | Treatments


WebCasts

Mediastinal large B-cell lymphoma

  

About Lymphoma > Types of Lymphoma > ??

Last update: 01/03/2008

 TOPIC SEARCH: ASCO.org | ASH.org | ASHeducation Books | JCO.org | Medscape (free login req.)
PubMed
| Systematic Review 

BackgroundResources | Treatments | Clinical Trials | References

Lymphomas Overview
ABOUT Lymphomas:

Overview of genes and cancer

Lymphoma is a cancer

About Lymphoma - general

Characteristics:
  Cell type | Histology | Grading | Staging

 Anne Arbor Staging 
  Extranodal notations  

 Diagnosis 

Host/tumor interactions
 

Lymphatic System

Prognostic Indicators

Risk Factors

Statistics
 
Staging
 
Symptoms

 
Transformation

 Guidelines at diagnosis
 
Treatment Decisions
 
Treatments
  
Return to top

 

Background:

"Primary Mediastinal B-cell lymphoma (PMBL/PMBCL)) is a diffuse large B-cell lymphoma that arises in the thymus and mainly affects young adults.  

Molecular diagnosis of Primary Mediastinal B Cell Lymphoma has identified it as a clinically favorable subgroup of Diffuse Large B Cell Lymphoma related to Hodgkin Lymphoma 2

Gene expression profile in PMBCL:

Primary mediastinal large B cell lymphoma (PMBCL) has been thought of as a special subtype of DLBCL. Its distinct clinical presentation in younger patients with a female predominance has led to the suspicion that it constitutes a unique entity. However, reliable distinction from DLBCL has remained elusive.

Gene expression analysis has settled the question and provided surprising insight into this lymphoma's unique biology, including similarities to Hodgkin lymphoma5. Based on a core cluster signature of 46 specific genes, 35 of which are relatively overexpressed in PMBCL and 11 in DLBCL, PMBCL can be quite accurately distinguished from all other types of large B cell lymphomas.

This unique gene expression signature includes a number of regulators of T cell activation, but, even more surprisingly, over one-third of the genes that are more highly expressed in PMBCL than in other large B cell lymphomas are also characteristically over-expressed in cells from putative (regarded as) Hodgkin lymphoma cell lines.

Of particular note is the overexpression of several genes associated with nuclear factor κ B (NFκB), revealing a pivotal role for this gene complex and suggesting possible points of attack for future therapeutic agents.

In the case of PMBCL, the application of gene expression profiling has provided not only improved accuracy of diagnosis and provocative suggestions for possible targets for new therapeutic agents, but also intriguing linkages to Hodgkin lymphoma.

SOURCE: Improving Diagnosis and Treatment of Lymphomas with Gene Expression Profiling, Joseph M. Connors, M.D.  - hematology.org  
 
"Major new insights into the biology of lymphomas have resulted from the use of microarray gene expression technology to elucidate their underlying biology and to identify novel pathways for therapeutic intervention."
See WHO Classification

____________________________________________
Incidence:  

Mediastinal large B-cell lymphoma is a rare form of non-Hodgkin's lymphoma, accounting for about 1 in 50 of all cases,

"In REAL classification PMBL is considered a variant of diffuse large B cell lymphoma." "PMBL accounts for about 2 percent of all non Hodgkins lymphoma." 1

Because of its skewed age distribution, PMBL accounts for a much higher proportion of both younger patients and those undergoing autologous transplantation. Uncertainty remains regarding the management of this disorder."  7

____________________________________________
Diagnosis:   

To make an accurate diagnosis of lymphoma, a biopsy must be performed by the surgical removal (resection) of a lymph node.   If the lymph nodes within the mediastinum are the only ones affected, the biopsy is likely to be taken during a procedure known as a mediastinoscopy.

A series of tests will then be performed to determine the characteristics of the cells.  If a malignancy is determine, these characteristics will allow your doctors to determine the appropriate treatments to use when needed. 

Specific markers: 

____________________________________________
Common signs and symptoms: 

bullet

breathlessness*

bullet

cough or chest pain*

bullet

fatigue

bullet

loss of appetite

bullet

enlarged lymph nodes - painless swelling in the neck, armpit or groin - often in more than one group..

Other symptoms may include night sweats, unexplained high temperatures and weight loss. These are known as B symptoms.

____________________________________________
Resources:
  1. Primary mediastinal B cell lymphoma (PMBL) in two sisters Year: 2002 
    Abstract No: 2646
  2. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma - jem.org 9_15_03
  3. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma - jem.org 9_15_03
  4. Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999. Session Type: Oral Session - ASH 2004
  5. Lymphomas: Non-Hodgkin Lymphoma - Medscape (free login req.)
  6. About Mediastinal large B-cell lymphoma - Cancerbackup
  7. About Mediastinal large B-cell lymphoma - Emedicine
____________________________________________
Treatment:

TOPIC SEARCH ASCO | Medscape | PubMed 

Some patients with early-stage primary mediastinal DLBCL (PMBCL), however, may require involved-field radiation after chemotherapy. 

In a study of 50 patients with untreated PMBCL who received MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) followed by radiation, 66% had a persistently positive gallium scan after chemotherapy alone, suggesting active disease.136 

However, treatment of PMBCL with other regimens that do not include involved-field radiation, such as ACVBP and DA-EPOCH, have yielded good results in PMBCL.71,135 Furthermore, rituximab has improved the outcome in DLBCL.79 Hence, it is reasonable to limit involved-field radiation to those patients with persistently positive PET scans after such treatments.  - Medscape  06/07/2006

bullet
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005 Sep;130(5):691-9. PMID: 16115124 

We conclude: (i) dose-dense chemotherapy with NHL-15 may be superior to CHOP for PMLBL; (ii) The impact of consolidative radiotherapy requires randomized controlled trials; (iii) The age-adjusted IPI did not predict survival in this analysis; (iv) high-dose chemotherapy/ASCT should be reserved for upfront anthracycline-based therapy failure or in clinical trials for high-risk patients.
bullet
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004 Jan 26;90(2):372-6. PMID: 14735179 

In our experience, MACOP-B/VACOP-B appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on mediastinum further improves the outcome of CR patients.
bullet
Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Ann Hematol. 2002 Jul;81(7):368-73. Epub 2002 Jun 21. PMID: 12185505 

We feel that patients with PMBCL should be treated with more intensive, but not myeloablative chemotherapy, followed by adjuvant radiotherapy to achieve an improvement in outcome in this setting of patients. Patients with pleural or pericardial effusion are considered at high risk for failure with the actual programs of treatment and probably will be considered for experimental therapeutic approaches.

____________________________________________
Clinical Trials:
Lymphoma-specific clinical trials by:

All for this type

Treatment type ...includes links to related PubMed abstracts

Other criteria ... includes filters for age, frontline, grade, phase, stage, and refractory disease

By State & Country

 

____________________________________________
Research News:
bullet
..

 

 
Disclaimer:  The information presented on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.